Transcarotid Arterial Revascularization of Symptomatic Internal Carotid Artery Disease : A Systematic Review and Study-Level Meta-Analysis
BACKGROUND: Transcarotid artery revascularization (TCAR) is an interventional therapy for symptomatic internal carotid artery disease. Currently, the utilization of TCAR is contentious due to limited evidence. In this study, we evaluate the safety and efficacy of TCAR in patients with symptomatic internal carotid artery disease compared with carotid endarterectomy (CEA) and carotid artery stenting (CAS).
METHODS: A systematic review was conducted, spanning from January 2000 to February 2023, encompassing studies that used TCAR for the treatment of symptomatic internal carotid artery disease. The primary outcomes included a 30-day stroke or transient ischemic attack, myocardial infarction, and mortality. Secondary outcomes comprised cranial nerve injury and major bleeding. Pooled odds ratios (ORs) for each outcome were calculated to compare TCAR with CEA and CAS. Furthermore, subgroup analyses were performed based on age and degree of stenosis. In addition, a sensitivity analysis was conducted by excluding the vascular quality initiative registry population.
RESULTS: A total of 7 studies involving 24 246 patients were analyzed. Within this patient cohort, 4771 individuals underwent TCAR, 12 350 underwent CEA, and 7125 patients underwent CAS. Compared with CAS, TCAR was associated with a similar rate of stroke or transient ischemic attack (OR, 0.77 [95% CI, 0.33-1.82]) and myocardial infarction (OR, 1.29 [95% CI, 0.83-2.01]) but lower mortality (OR, 0.42 [95% CI, 0.22-0.81]). Compared with CEA, TCAR was associated with a higher rate of stroke or transient ischemic attack (OR, 1.26 [95% CI, 1.03-1.54]) but similar rates of myocardial infarction (OR, 0.9 [95% CI, 0.64-1.38]) and mortality (OR, 1.35 [95% CI, 0.87-2.10]).
CONCLUSIONS: Although CEA has traditionally been considered superior to stenting for symptomatic carotid stenosis, TCAR may have some advantages over CAS. Prospective randomized trials comparing the 3 modalities are needed.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Stroke - 55(2024), 4 vom: 01. März, Seite 921-930 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghannam, Malik [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carotid stenosis |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 29.03.2024 published: Print-Electronic CommentIn: Stroke. 2024 Apr;55(4):931-933. - PMID 38299387 Citation Status MEDLINE |
|---|
| doi: |
10.1161/STROKEAHA.123.044246 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367886464 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367886464 | ||
| 003 | DE-627 | ||
| 005 | 20240330000851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240201s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/STROKEAHA.123.044246 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM367886464 | ||
| 035 | |a (NLM)38299350 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghannam, Malik |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transcarotid Arterial Revascularization of Symptomatic Internal Carotid Artery Disease |b A Systematic Review and Study-Level Meta-Analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Stroke. 2024 Apr;55(4):931-933. - PMID 38299387 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Transcarotid artery revascularization (TCAR) is an interventional therapy for symptomatic internal carotid artery disease. Currently, the utilization of TCAR is contentious due to limited evidence. In this study, we evaluate the safety and efficacy of TCAR in patients with symptomatic internal carotid artery disease compared with carotid endarterectomy (CEA) and carotid artery stenting (CAS) | ||
| 520 | |a METHODS: A systematic review was conducted, spanning from January 2000 to February 2023, encompassing studies that used TCAR for the treatment of symptomatic internal carotid artery disease. The primary outcomes included a 30-day stroke or transient ischemic attack, myocardial infarction, and mortality. Secondary outcomes comprised cranial nerve injury and major bleeding. Pooled odds ratios (ORs) for each outcome were calculated to compare TCAR with CEA and CAS. Furthermore, subgroup analyses were performed based on age and degree of stenosis. In addition, a sensitivity analysis was conducted by excluding the vascular quality initiative registry population | ||
| 520 | |a RESULTS: A total of 7 studies involving 24 246 patients were analyzed. Within this patient cohort, 4771 individuals underwent TCAR, 12 350 underwent CEA, and 7125 patients underwent CAS. Compared with CAS, TCAR was associated with a similar rate of stroke or transient ischemic attack (OR, 0.77 [95% CI, 0.33-1.82]) and myocardial infarction (OR, 1.29 [95% CI, 0.83-2.01]) but lower mortality (OR, 0.42 [95% CI, 0.22-0.81]). Compared with CEA, TCAR was associated with a higher rate of stroke or transient ischemic attack (OR, 1.26 [95% CI, 1.03-1.54]) but similar rates of myocardial infarction (OR, 0.9 [95% CI, 0.64-1.38]) and mortality (OR, 1.35 [95% CI, 0.87-2.10]) | ||
| 520 | |a CONCLUSIONS: Although CEA has traditionally been considered superior to stenting for symptomatic carotid stenosis, TCAR may have some advantages over CAS. Prospective randomized trials comparing the 3 modalities are needed | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a carotid stenosis | |
| 650 | 4 | |a perioperative complications | |
| 650 | 4 | |a symptomatic | |
| 650 | 4 | |a transcarotid artery revascularization | |
| 700 | 1 | |a AlMajali, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Khasiyev, Farid |e verfasserin |4 aut | |
| 700 | 1 | |a Dibas, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Al Qudah, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a AlMajali, Fawaz |e verfasserin |4 aut | |
| 700 | 1 | |a Ghazaleh, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Asghar |e verfasserin |4 aut | |
| 700 | 1 | |a Fayad, Fayez H |e verfasserin |4 aut | |
| 700 | 1 | |a Joudi, Kareem |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidat, Bashar |e verfasserin |4 aut | |
| 700 | 1 | |a Childs, Christopher A |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Bennett R |e verfasserin |4 aut | |
| 700 | 1 | |a Abouainain, Yasmeen |e verfasserin |4 aut | |
| 700 | 1 | |a Özdemir-van Brunschot, Denise M D |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Liqi |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, Eric D |e verfasserin |4 aut | |
| 700 | 1 | |a Baig, Ammad A |e verfasserin |4 aut | |
| 700 | 1 | |a Roeder, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Henninger, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a de Havenon, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Elad I |e verfasserin |4 aut | |
| 700 | 1 | |a Matouk, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Derdeyn, Colin P |e verfasserin |4 aut | |
| 700 | 1 | |a Leira, Enrique C |e verfasserin |4 aut | |
| 700 | 1 | |a Chaturvedi, Seemant |e verfasserin |4 aut | |
| 700 | 1 | |a Yaghi, Shadi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke |d 1970 |g 55(2024), 4 vom: 01. März, Seite 921-930 |w (DE-627)NLM000010995 |x 1524-4628 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2024 |g number:4 |g day:01 |g month:03 |g pages:921-930 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/STROKEAHA.123.044246 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2024 |e 4 |b 01 |c 03 |h 921-930 | ||